Abstract
The natural course of Crohns disease is characterized by the progression from primarily inflammatory disease to a complicated stricturing or penetrating disease. These irreversible complications lead to repeated surgery and considerable disability. Therefore it may be argued that a window of opportunity for intensive treatment exists early in the disease course. Healing of the mucosa has been shown to be a strong predictor of improved outcome of Crohns disease on the long-term, in terms of disease control, hospitalizations, and surgery. Anti-tumor necrosis factor (TNF)-α therapy has shown to be a strong inducer of mucosal healing and it may be argued that early treatment with anti-TNFs and/or immunomodulators may be the preferable approach in selected patients. The main concern with such strategies is safety, especially the risk of lymphomas and infections. This paper aims to review the existing data regarding the benefits and disadvantages of inverting the classic step up therapeutic paradigm.
Keywords: Crohn's disease, top-down, step-up, tumor necrosis factor-α, immunomodulators, mucosal healing, course of disease, immunosuppression
Current Drug Targets
Title: Anti-TNF and Crohns Disease: When Should we Start?
Volume: 11 Issue: 2
Author(s): H. H. Fidder and D. W. Hommes
Affiliation:
Keywords: Crohn's disease, top-down, step-up, tumor necrosis factor-α, immunomodulators, mucosal healing, course of disease, immunosuppression
Abstract: The natural course of Crohns disease is characterized by the progression from primarily inflammatory disease to a complicated stricturing or penetrating disease. These irreversible complications lead to repeated surgery and considerable disability. Therefore it may be argued that a window of opportunity for intensive treatment exists early in the disease course. Healing of the mucosa has been shown to be a strong predictor of improved outcome of Crohns disease on the long-term, in terms of disease control, hospitalizations, and surgery. Anti-tumor necrosis factor (TNF)-α therapy has shown to be a strong inducer of mucosal healing and it may be argued that early treatment with anti-TNFs and/or immunomodulators may be the preferable approach in selected patients. The main concern with such strategies is safety, especially the risk of lymphomas and infections. This paper aims to review the existing data regarding the benefits and disadvantages of inverting the classic step up therapeutic paradigm.
Export Options
About this article
Cite this article as:
Fidder H. H. and Hommes W. D., Anti-TNF and Crohns Disease: When Should we Start?, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309993
DOI https://dx.doi.org/10.2174/138945010790309993 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists
Recent Patents on Anti-Cancer Drug Discovery Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Synthesis and Anticancer Evaluation of Thiazacridine Derivatives Reveals New Selective Molecules to Hematopoietic Neoplastic Cells
Combinatorial Chemistry & High Throughput Screening Platinum-Intercalator Conjugates: From DNA-Targeted Cisplatin Derivatives to Adenine Binding Complexes as Potential Modulators of Gene Regulation
Current Topics in Medicinal Chemistry EBV-Associated Tumors: Pathogenetic Insights for Improved Disease Monitoring and Treatment
Current Cancer Therapy Reviews A Rare Diagnosis in a Patient With Pelvic Pain: Adnexal Schwannoma
Current Medical Imaging Synthesis and Biological Activity of 28-Amide Derivatives of 23-Hydroxy Betulinic Acid as Antitumor Agent Candidates
Medicinal Chemistry Mechanisms of Interferon Mediated Anti-Viral Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design Stereoselective Synthesis of Pyroglutamate Natural Product Analogs from α- Aminoacids and their Anti-Cancer Evaluation
Anti-Cancer Agents in Medicinal Chemistry Current Treatments of Muco-Cutaneous Herpes Simplex Virus Infections
Current Medicinal Chemistry - Anti-Infective Agents Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer
Current Drug Targets Oxidative Stress Upregulates PDCD4 Expression in Patients with Gastric Cancer via miR-21
Current Pharmaceutical Design Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Current Cancer Drug Targets MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design